Skip to main navigation

Investors
News Releases
Events & Presentations
Stock Information
Corporate Governance
SEC Filings
IR Resources

News Releases

News Releases

Year

November 21, 2019

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration

November 12, 2019

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

November 6, 2019

Harpoon Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

October 29, 2019

Harpoon Therapeutics Presents Preclinical Data for HPN328, a DLL3-targeting T Cell Engager, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 22, 2019

Harpoon Therapeutics Announces Presentation on HPN328 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

August 28, 2019

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

August 5, 2019

Harpoon Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

July 31, 2019

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

May 9, 2019

Harpoon Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

April 18, 2019

Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T cell Engager (HPN536) in Phase 1/2a Clinical Trial for Ovarian and Other Solid Tumor Cancers

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Next page
Last page

Email Alerts

RSS Feeds

Contact IR

Search

© 2021. Harpoon Therapeutics, Inc. All rights reserved.

Search Investor Relations